For GSK, Lots Of Drugs In R&D, But Many Are Long-Term
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline PLC held an expansive R&D update Nov. 3, laying out a strategy to file up to 20 drugs with regulators before 2020, seven of which could launch in that timeline. But few investors are likely to walk away from the four-hour meeting with a changed sentiment on the firm in the near-term, where it is facing strong headwinds from slowing sales of its top-seller Advair Diskus.
You may also be interested in...
Bayer Wary Of Future Competition In Renal Anemia Market
The race to market for HIF-PH inhibitors to treat anemia associated with chronic kidney disease is highly competitive and will be complicated by the expected launch of biosimilar erythropoiesis-stimulating agents.
GSK Positions To Dominate In Vaccines; Will The Bet Pay Off?
The British pharma outlined its strategy for winning as one of the world’s leading vaccines makers May 6, two months after completing the acquisition of Novartis’ vaccines business.
As Teva's Neurology Portfolio Gains Momentum, New Assets Join The Pipeline
Q3 results show Austedo appears headed towards blockbuster status, and the company signed a collaboration with MODAG for two compounds for neurodegenerative diseases.